Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Moderna, Inc. (MRNA) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

Moderna, Inc.Trade
Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

Moderna, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Moderna, Inc. trades at $60.75 (market cap $24.18B), while Vertex Pharmaceuticals Incorporated trades at $529.98 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 5.6× Moderna, Inc.'s market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.

MRNAVRTX
Market Cap
$24.18B$134.25B
Sector
HealthHealth
52-Week High
$81.80$529.65
52-Week Low
$22.36$376.62
Enterprise Value
$20.33B$128.37B

Returns comparison

Trailing returns across standard periods

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Read more on VRTX